More than two-thirds of women classified as high-risk for breast cancer recurrence were safely spared chemotherapy after a genomic test guided their treatment decisions, according to results from the OPTIMA trial. The study, sponsored by University College London and launched at University College London Hospitals, used the Prosigna assay to sort patients with hormone-receptor positive, HER2-negative disease into groups that did or did not need chemotherapy. The finding directly challenges the long-standing default of prescribing chemotherapy to nearly all patients whose clinical features suggest elevated recurrence risk.
Why Prosigna’s chemotherapy-sparing result matters right now
Thousands of breast cancer patients each year receive chemotherapy based on clinical markers like tumor size and lymph node involvement, even when the actual benefit of that treatment is uncertain. Chemotherapy carries well-documented side effects, from nausea and fatigue to long-term cardiac damage and cognitive changes. The OPTIMA trial set out to answer a specific question: could a gene expression test reliably identify which patients could skip chemotherapy without sacrificing outcomes?
The answer, based on the trial’s results, is that more than two-thirds of patients could avoid chemotherapy without compromising their prognosis. That ratio is striking because these were not low-risk patients by conventional standards. They were women whose tumors and clinical profiles would typically have prompted oncologists to recommend a full course of chemotherapy. For this group, the ability to forgo chemotherapy means avoiding months of treatment and years of potential late effects without giving up the protection against recurrence that systemic therapy is meant to provide.
One open question is whether the timing of Prosigna testing could amplify its impact. In the OPTIMA framework, the test was used after surgery to guide decisions about follow-up treatment. But if Prosigna results were available before surgery, they could potentially reshape the surgical plan itself, influencing decisions about the extent of tissue removal or the need for axillary node dissection. Pre-surgical testing might therefore produce even larger chemotherapy-sparing effects by altering the entire treatment pathway, not just the post-operative drug regimen. No published OPTIMA data directly tests this hypothesis, but the logic follows from how genomic risk scores interact with staging decisions. Clinicians who already know a tumor’s molecular profile before operating may be less inclined toward aggressive surgical and systemic approaches when the biology signals low recurrence risk.
The result also matters for health systems under pressure. Chemotherapy is expensive to deliver and resource-intensive, requiring infusion capacity, specialist nursing, and supportive medications. If a validated genomic test can reliably identify a majority of clinically high-risk patients who can avoid chemotherapy, the downstream savings in costs and clinic time could be substantial. For patients, those system-level gains translate into more timely access to other services and, potentially, shorter waiting lists for those who do need chemotherapy.
How OPTIMA selected Prosigna and built its evidence base
The OPTIMA trial did not arrive at Prosigna by default. An earlier feasibility phase, known as OPTIMA prelim, compared several genomic assays head to head before selecting one for the full-scale trial. That feasibility study was a randomised effort funded by the National Institute for Health and Care Research, and it tested whether patients could be recruited, randomised, and managed using a genomic-test-guided strategy in routine NHS settings. Investigators examined practical questions such as turnaround times for test results, clinicians’ willingness to follow genomic guidance, and patients’ acceptance of being assigned to chemotherapy or no chemotherapy based on a molecular score.
After evaluating the competing platforms, the investigators chose Prosigna for the main phase III trial. Prosigna is built on the PAM50 gene expression signature, which reads 50 genes to classify tumors into molecular subtypes and generate a risk-of-recurrence score. Unlike clinical markers alone, which rely on tumor size, grade, and node status, PAM50 captures the biological behavior of the cancer at a molecular level. Two tumors that look identical under a microscope can have very different PAM50 scores, and those scores predict different outcomes. That biological precision is what allowed the OPTIMA investigators to identify a large group of clinically high-risk patients whose molecular profiles suggested they would do well without chemotherapy.
OPTIMA sits within a broader wave of trials testing whether genomic assays can safely de-escalate treatment. The RxPONDER trial, registered as NCT01272037, tested a similar concept in patients with hormone-receptor positive, HER2-negative breast cancer and positive lymph nodes, using a different genomic platform. In that study, women with a low genomic risk score and limited nodal involvement were randomised to endocrine therapy with or without chemotherapy. The design mirrors OPTIMA’s core question: can a molecular signature substitute for traditional high-risk features when deciding who truly benefits from cytotoxic treatment?
Together, these trials are building a case that molecular profiling can replace blanket chemotherapy recommendations for a defined subset of patients. But the OPTIMA results stand out for the sheer proportion of patients who were spared treatment, and for the trial’s design within a public health system where adoption could be rapid if the evidence holds. Embedding the study in NHS hospitals means that the logistics, costs, and patient pathways tested in OPTIMA resemble real-world practice, which may smooth the transition from research finding to routine care.
Gaps in the OPTIMA data that patients and clinicians should track
The headline result is compelling, but several pieces of the evidence remain incomplete. Full phase III efficacy and safety tables from OPTIMA have not yet appeared in the primary NIHR or ClinicalTrials.gov records. The topline finding that more than two-thirds of patients avoided chemotherapy without compromised outcomes comes from the UCL institutional release, which does not include raw survival data, confidence intervals, or subgroup breakdowns by node status. Until those details are published in a peer-reviewed journal, oncologists will have limited ability to assess exactly which patients benefit most from the test and whether any subgroups were under-served by the genomic-guided approach.
Long-term overall survival and quality-of-life endpoints are also outstanding. Breast cancer recurrence can happen years or even decades after initial treatment, especially in hormone-receptor positive disease. Without extended follow-up, it remains possible that small differences in recurrence rates could emerge over time between patients who received chemotherapy and those who did not. Similarly, formal quality-of-life data will be important to quantify the trade-offs between avoiding chemotherapy toxicity and living with any lingering anxiety about recurrence when treatment is de-escalated.
Another gap involves how Prosigna performs across diverse patient populations. The OPTIMA cohort was drawn from UK centres, and the available summaries do not yet detail representation by age, ethnicity, or comorbidities. If certain groups were under-represented, clinicians will need to be cautious about generalising the results until additional data or real-world studies confirm that the assay’s risk predictions hold across broader populations. This is particularly relevant for younger women, who often face more aggressive disease and may weigh even small potential benefits from chemotherapy differently.
Health-economic analyses will also be closely watched. While genomic testing adds an upfront cost, it may reduce overall spending by eliminating unnecessary chemotherapy and its complications. A robust cost-effectiveness assessment, ideally stratified by health system and test price, will help policymakers decide whether to fund widespread Prosigna testing for eligible patients. Without that analysis, adoption may be uneven, with some hospitals embracing the assay and others waiting for clearer financial guidance.
For now, the OPTIMA findings suggest a future in which treatment for hormone-receptor positive, HER2-negative breast cancer is more precisely tailored to tumor biology rather than dictated by broad clinical categories. Patients and clinicians should watch for the full publication of the phase III data, including detailed survival curves, subgroup analyses, and quality-of-life results. Those numbers will determine whether Prosigna-guided care becomes a new standard for high-risk early breast cancer or remains an option reserved for select cases. What is already clear is that genomic testing has moved from a theoretical tool to a practical instrument capable of reshaping chemotherapy decisions for a large share of patients.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
